CEO Kevin Tang's Entities Detail $12.4M Stock Purchases, Hold Put Options
Summary
CEO Kevin Tang's affiliated entities disclosed over $12.4 million in recent stock purchases and hold put options, signaling strong confidence in Aurinia Pharmaceuticals.
Key Events
-
CEO-Affiliated Entities Increase Stake
Entities managed by CEO Kevin Tang, including Tang Capital Management, LLC, beneficially own 13,044,106 common shares, representing 10.0% of outstanding shares.
-
Over $12.4 Million in Recent Stock Purchases
Between May 29 and June 2, 2026, Tang Capital entities purchased 814,606 shares at an average price of approximately $15.30 per share, totaling over $12.4 million.
-
Bullish Put Option Position
The reporting persons have potential obligations to purchase 1,000,000 common shares at a strike price of $15.00, expiring January 15, 2027, indicating a bullish outlook.
-
CEO's Role Explicitly Stated
The amendment explicitly states Kevin Tang's role as the manager of Tang Capital Management, LLC, and as a member of the Board of Directors and Chief Executive Officer of Aurinia Pharmaceuticals Inc.
Analysis
This Schedule 13D/A details recent open-market purchases totaling over $12.4 million by entities affiliated with CEO Kevin Tang, reinforcing his significant stake in the company. The filing also reveals potential obligations to acquire an additional 1 million shares through put options, signaling further bullish conviction. These actions by the new CEO provide a strong counter-signal to recent Form 144 filings by other executives intending to sell shares, and come as the company announced positive clinical data.
At the time of this filing, AUPH was trading at $16.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $7.29 to $16.88. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.